Lairesp

Oxymetazoline, the active ingredient in Lairesp, is a Alpha-adrenergic agonist presented as a nasal spray for nasal use. It provides temporary relief of nasal congestion associated with colds, allergic rhinitis and sinusitis in adults and children. GNH USA supplies Lairesp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxymetazoline is an alpha‑adrenergic agonist used to relieve congestion in the upper respiratory tract. - Nasal congestion: reduces swelling of nasal mucosa for quick airflow improvement. - Allergic rhinitis: alleviates blockage caused by allergic inflammation. - Common cold: eases temporary nasal blockage during viral upper respiratory infections.

Oxymetazoline may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal mucosa - Sneezing - Mild headache - Altered taste perception - Transient epistaxis (nosebleed)

Serious or Rare Side Effects: - Rebound nasal congestion (rhinitis medicamentosa) with prolonged use - Elevated blood pressure or hypertension - Cardiac arrhythmias in susceptible individuals - Severe nasal ulceration or tissue damage - Allergic reactions including rash, itching or anaphylaxis

Before using Lairesp, consider the following safety measures. - Duration of use: limit to three consecutive days to avoid rebound congestion. - Pregnancy: consult a healthcare professional before use. - Breastfeeding: discuss potential risks with a physician. - Children under 6 years: not recommended unless directed by a clinician. - Concurrent nasal surgery or trauma: avoid use until cleared by a surgeon. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Oxymetazoline may interact with other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other topical nasal decongestants (e.g., phenylephrine): additive vasoconstriction may increase cardiovascular strain. - Systemic sympathomimetics: may amplify blood pressure effects.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: possible reduction in blood‑pressure‑lowering efficacy. - Beta‑blockers: may blunt cardiovascular response. - Tricyclic antidepressants or SSRIs: monitor for increased sympathetic activity.